2025 was the year computational biology shed its reliance on surface-level summaries. While everyone talked about biological foundation models maturing, the papers that actually moved the needle were those that either solved gnarly technical problems (long-read isoform identification, variant calling in RNA-seq) or built guardrails around AI claims. Three themes dominated: isoform complexity finally being mapped with confidence, machine learning models that admit what they don’t know, and multi-omics integration at scale revealing new disease mechanisms. Here are five papers that will reshape how you analyze and interpret your data in 2026.
Xu et al., 2025: Isoform Switching in Autism Risk Genes
Long-read proteogenomic atlas of human neuronal differentiation reveals isoform diversity informing neurodevelopmental risk mechanisms — Xu et al., bioRxiv, December 2025
Xu and colleagues performed deep long-read RNA sequencing plus proteomics on iPSC-derived cortical neurons across differentiation stages, identifying 182,371 mRNA isoforms (over half previously unknown). The real insight: autism spectrum disorder risk genes undergo dynamic isoform switching during neuron maturation, including microexon inclusion and intron retention that remodel key protein domains. They validated these discoveries with peptide evidence, proving the isoforms actually translate.
This matters because most variant interpretation pipelines still assume one isoform per gene. If your ASD patient carries a variant in an exon that’s only included in one neurodevelopmental stage, or only in a specific neuronal subtype, you’ll miss it using bulk annotations. This atlas provides the isoform-level resolution needed.
Zheng et al., 2025: Calling Variants in RNA Reliably
Clair3-RNA: a deep learning-based small variant caller for long-read RNA sequencing data — Zheng et al., Nature Communications, December 2025
Long-read RNA-seq had a problem: high error rates and RNA editing events made variant calling noisy. Zheng et al. built Clair3-RNA, a deep learning variant caller tailored for long-read RNA data from both PacBio and Oxford Nanopore. On the latest ONT kits, it achieves ~91% SNP F1-score; with 10x coverage it exceeds 95%. After haplotype phasing, performance reaches 97 to 98% depending on platform.
If you’re doing lrRNA-seq and wanted to call variants but didn’t trust the results, this tool removes that excuse. It handles RNA editing explicitly and works across platforms, so the barrier to variant discovery in transcriptomics just dropped.
Yin et al., 2025: Evidence-Grounded AI for Drug Target Discovery
An Evidence-Grounded Research Assistant for Functional Genomics and Drug Target Assessment — Yin et al., bioRxiv, December 2025
Large language models in biomedicine made grand promises but kept hallucinating. Alvessa changes that by tying every claim to retrieved evidence: it integrates entity recognition, orchestrates pre-validated biological databases, and flags unsupported statements explicitly. Tested on GenomeArena (720 questions spanning variant annotation, pathways, drug-target evidence, protein structures), Alvessa outperformed general-purpose language models and produces fully traceable outputs. For drug discovery, evidence-grounded synthesis identified candidate targets missed by literature-centered reasoning alone.
This is critical infrastructure for computational biologists using AI. You finally get traceability. When Alvessa says “BRCA1 interacts with RAD51,” you can click through and see exactly where it pulled that from. Your collaborators will stop dismissing your AI-assisted findings because you can show your work.
Song et al., 2025: Tumor Microenvironment Prognostics from Multi-Omics
Decoding hepatocellular carcinoma prognosis: a machine learning-derived methylation signature integrating transcriptomic and tumor microenvironment insights — Song et al., International Journal of Surgery, November 2025
Song et al. applied machine learning to hundreds of algorithm combinations on TCGA HCC data, integrating transcriptomics, methylation, and single-cell RNA-seq. They identified a 10-gene methylation signature that outperformed standard clinicopathological parameters for predicting overall survival. Spatial transcriptomics revealed these genes cluster in immune cell populations, cancer-associated fibroblasts, and metabolic pathways.
The lesson: if your prognostic model is built on expression alone, you’re missing half the biology. Multi-omics integration is now table stakes, and single-cell + spatial data let you see which cell types drive your signal. This approach scales to other cancer types.
Zheng et al., 2025: Handling Replicates in Long-Read Studies
To join or not to join: handling biological replicates in long-read RNA sequencing data — Zheng et al., bioRxiv, December 2025
A seemingly technical question with surprising implications: when you have multiple samples of long-read RNA-seq, should you pool reads (“Join & Call”) or call transcripts per sample then merge (“Call & Join”)? Testing six tools on mouse brain and kidney across PacBio and ONT, Zheng found the answer depends on your goal. Join & Call discovers rare isoforms better (pooling boosts low-coverage signal). Call & Join is faster and sufficient if rare transcript discovery isn’t your objective.
For labs starting large-scale lrRNA-seq studies, this framework saves months of wasted analysis. It’s a small paper that solves a real problem.
What to Watch in Early 2026
The computational biology pipeline of 2026 will assume isoform-level annotation, not gene-level. Variant callers will work on RNA, not just DNA. Machine learning will be traced and verifiable. Multi-omics will be routine. And long-read technology will be commodity. Start updating your protocols now. The papers above aren’t hype; they’re solving tangible problems that blocked real research. That’s what matters.
Related posts:
- Check out our analysis of DESeq2 vs edgeR vs limma-voom for RNA-seq differential expression best practices.
- For spatial approaches to tumor biology, see Spatial Transcriptomics Maps Immune Exclusion in Tumors